NYSE - Nasdaq Real Time Price USD

CONMED Corporation (CNMD)

Compare
65.20 -1.39 (-2.09%)
As of 12:12 PM EDT. Market Open.
Loading Chart for CNMD
DELL
  • Previous Close 66.59
  • Open 66.29
  • Bid 65.30 x 900
  • Ask 65.44 x 1200
  • Day's Range 65.16 - 66.41
  • 52 Week Range 61.05 - 117.27
  • Volume 139,213
  • Avg. Volume 426,842
  • Market Cap (intraday) 2.01B
  • Beta (5Y Monthly) 1.46
  • PE Ratio (TTM) 20.76
  • EPS (TTM) 3.14
  • Earnings Date Oct 23, 2024 - Oct 28, 2024
  • Forward Dividend & Yield 0.80 (1.20%)
  • Ex-Dividend Date Sep 16, 2024
  • 1y Target Est 83.71

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

www.conmed.com

4,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CNMD

View More

Performance Overview: CNMD

Trailing total returns as of 10/7/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CNMD
40.00%
S&P 500
20.10%

1-Year Return

CNMD
32.79%
S&P 500
32.96%

3-Year Return

CNMD
50.95%
S&P 500
31.28%

5-Year Return

CNMD
29.63%
S&P 500
94.05%

Compare To: CNMD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CNMD

View More

Valuation Measures

Annual
As of 10/4/2024
  • Market Cap

    2.05B

  • Enterprise Value

    2.99B

  • Trailing P/E

    21.21

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.64

  • Price/Book (mrq)

    2.33

  • Enterprise Value/Revenue

    2.34

  • Enterprise Value/EBITDA

    12.76

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.73%

  • Return on Assets (ttm)

    3.92%

  • Return on Equity (ttm)

    11.86%

  • Revenue (ttm)

    1.28B

  • Net Income Avi to Common (ttm)

    98.59M

  • Diluted EPS (ttm)

    3.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.87M

  • Total Debt/Equity (mrq)

    109.53%

  • Levered Free Cash Flow (ttm)

    128.14M

Research Analysis: CNMD

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 332.1M
Earnings 29.98M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

71.00
83.71 Average
65.20 Current
102.00 High
 

Company Insights: CNMD

Research Reports: CNMD

View More
  • Lowering target price to $72.00

    CONMED CORP has an Investment Rating of HOLD; a target price of $72.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
     
  • Raising target price to $80.00

    CONMED CORP has an Investment Rating of HOLD; a target price of $80.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
     
  • Raising target price to $79.00

    CONMED CORP has an Investment Rating of HOLD; a target price of $79.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
     
  • Raising target price to $76.00

    CONMED CORP has an Investment Rating of HOLD; a target price of $76.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
     

People Also Watch